IO-Monotherapy in Non-Small Cell Lung Cancer?

The most favorable data sets are non-small cell lung cancer, at least using either monotherapy or combinations with chemo-therapy and immunotherapy have been with PDO1 inhibitors. In terms of preference, I must admit I do generally use Pembrolyzema. The one agent that also has approved that is the tesalizema data set. But interestingly, the data hasn't held up very well over time. It's a little bit hard to make broad generalizations across the class between PDO1 and PDO1.